Core Viewpoint - Bayer has signed agreements with Chengdu Lingtai Ke Biotechnology Co., Ltd. and Hangzhou Tengzhi Biopharmaceutical Technology Co., Ltd. to join the Bayer Co.Lab co-creation platform, aiming to leverage Bayer's global innovation network to accelerate breakthroughs in new technology platforms in the biopharmaceutical industry [1][2]. Group 1: Company Collaborations - Tengzhi Biopharmaceutical is focused on the discovery of cyclic peptide drugs and has developed an efficient platform for discovering cyclic peptides, which has led to multiple clinically promising candidate molecules [3][4]. - Lingtai Ke Biotechnology is committed to developing innovative therapeutic methods for diseases with unmet clinical needs, utilizing long non-coding RNA (lncRNA) for targeted drug delivery [4][5]. - Both companies aim to leverage Bayer's resources and expertise to accelerate their innovation processes and bring new therapies to patients globally [1][3][4]. Group 2: Bayer Co.Lab Overview - Bayer Co.Lab is designed to promote open collaboration in the biopharmaceutical ecosystem and accelerate the innovation process of cutting-edge technologies [5]. - The platform plans to empower 10 to 15 local startups, focusing on areas such as oncology, cardiovascular diseases, new technology platforms, and cell and gene therapies [5]. - Currently, five Chinese biotechnology startups have signed agreements to join Bayer Co.Lab, which will utilize Bayer's global open innovation network and industry expertise to enhance their development [5].